Drug Name: Rivfloza

Active Ingredient: nedosiran

Indications: To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

Approval Date: 9/29/2023

Company: Dicerna Pharmaceuticals, Inc. (a Novo Nordisk company)

More:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *